Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-09-30 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a future event: a scientific symposium organized by Innate Pharma on October 3, 2024. It details the event's purpose, speakers, and location. It also mentions a separate meeting for investors and analysts scheduled before the symposium. Since the document is an announcement about an upcoming event (a scientific symposium and an investor meeting) rather than a formal regulatory filing (like 10-K, IR, or ER) or the presentation material itself, it best fits the category for general regulatory announcements or communications that don't fit elsewhere. Given the options, this is a general corporate communication. While it relates to investor relations, it is not a formal Earnings Release (ER), Interim Report (IR), or Investor Presentation (IP) itself, but rather an announcement *about* an event. The closest fit among the specific categories for a general, non-statutory announcement of a corporate event is often RNS (Regulatory Filings/General Announcements), or potentially IP if the symposium content was the primary focus, but since it's an announcement *of* the symposium, RNS is the most appropriate fallback for a press release detailing corporate activities that isn't a core financial report.
2024-09-30 French
6-K
Foreign Filer Report
2024-09-23 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant corporate event: the FDA clearance of an Investigational New Drug (IND) application for a product candidate (IPH4502). This type of announcement, detailing clinical trial initiation, scientific progress, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification for a major, time-sensitive operational/clinical update is Earnings Release (ER), as these often accompany or substitute for formal quarterly updates when major news breaks. It is a direct announcement of results/progress, not an announcement *about* a report (RPA).
2024-09-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant operational update: the FDA authorization to initiate clinical development for a new drug candidate (IPH4502). This type of announcement, focusing on regulatory milestones, clinical trial initiation, and pipeline progress, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing key operational news rather than a full quarterly/annual report (10-K or IR) or a transcript (CT), and it is not a specific announcement like a dividend (DIV) or management change (MANG), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the nature of the announcement (FDA clearance for clinical trial initiation), it is a material event disclosure. While it could be RNS, ERs often include such material updates alongside or instead of formal quarterly results. However, since it is a press release announcing a major clinical development milestone, and not explicitly tied to quarterly financial results, the most appropriate general category for a material, non-standard announcement is often RNS, or ER if it's a standard practice for the company to release pipeline updates this way. Given the content is purely operational/clinical progress announced via a press release, and it's not a formal financial report, RNS (Regulatory Filings/General Announcement) is a strong candidate. However, many companies issue press releases for clinical updates that are functionally similar to an Earnings Release in terms of market impact, even if not tied to the exact earnings date. Since the document is a press release announcing a major clinical development milestone (FDA clearance to start Phase 1), and it is not a full financial report, it is classified as an Earnings Release (ER) as these often encompass key operational achievements, or RNS as a fallback. Given the focus on a specific drug development step, it is a material event disclosure. I will classify it as ER as these releases often contain key operational highlights, but RNS is also plausible. Given the lack of explicit financial figures or quarterly context, RNS is safer as a general regulatory announcement.
2024-09-23 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 30 JUIN 2024' (Half-Year Financial Report as of June 30, 2024). It contains comprehensive financial statements, including the consolidated statement of financial position, income statement, cash flow statement, and notes to the financial statements, as well as a management discussion and analysis (Rapport semestriel d'activité). It is a full interim report for a period shorter than a fiscal year, not an announcement or a summary. H1 2024
2024-09-12 French
6-K
Foreign Filer Report
2024-09-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.